An open label Randomized Controlled Clinical trial to Evaluate the Safety and Efficacy of selected Siddha formulations in patients diagnosed with COVID-19

ational Institute of Siddha0 个研究点目标入组 215 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Male, Female and Transgenders.
•ï?· Age between 18 to 85 years
•ï?· COVID 19 positive asymptomatic / pre symptomatic, mild, moderate and severe COVID patients.
•ï?· Willing to consent to the study.

•Patients who cannot take food or drugs orally. High risk groups (Patients with Complications of Diabetes â?? DKA, DN, Severe Heart diseases and Pregnancy)
•Patients with other severe medical conditions requiring intensive management.
•Other viral pneumonia
•Patients who have received organ transplantation in the past 6 months or planning surgery
•Patients with severe or critical covid-19 infections.
•Patients with any active malignancy
•Patients who have severe underlying diseases that affects survival, including blood diseases,
•dyscrasia, active bleeding, severe malnutrition, etc.
•Patients with allergic constitution, or patients allergic to investigational products
•Patients with a history of positivity for HIV, Hepatitis B and Hepatitis C at screening.
•Critical patients with life expectancy <48 hours
•Septicemia / Multi-organ failure Syndrome (MODS).
•Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal.
•Patients participating in other COVID 19 trials.

发起方